Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14)

Market Cap	5.19B +33.1%
Revenue (ttm)	904.27M -32.7%
Net Income	391.88M -4.4%
EPS	0.51 -4.2%
Shares Out	n/a
PE Ratio	13.25
Forward PE	n/a
Dividend	0.67 (21.01%)
Ex-Dividend Date	Jan 30, 2026

Volume	482,600
Average Volume	165,590
Open	3.220
Previous Close	3.210
Day's Range	3.220 - 3.430
52-Week Range	2.160 - 3.750
Beta	n/a
RSI	63.33
Earnings Date	Apr 30, 2026

About SGX:T14

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited engages in the research, development, processing, manufacturing, and sale of traditional Chinese medicine in China. It provides pharmaceutical products for cardiovascular and cerebrovascular, skin wound repair, health preservation, respiratory, digestion, rheumatism and osteodynia, urological, gynecological and pediatric, ophthalmological, tumor, chronic, and other diseases, as well as tonic drugs. The company was formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Li...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1915
• Employees: 3,890
• Stock Exchange: Singapore Exchange
• Ticker Symbol: T14

Financial Performance

In 2025, SGX:T14's revenue was 4.92 billion, a decrease of -32.70% compared to the previous year's 7.31 billion. Earnings were 2.13 billion, a decrease of -4.41%.

Financial numbers in CNY